bufogenin has been researched along with Colorectal Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, DL; Bai, JJ; Cao, GC; Gao, WD; Hao, TT; Ma, Y; Qi, WH; Shen, LD; Zong, XL; Zuo, CY | 1 |
| Chen, C; Dai, Y; Han, Q; Jing, L; Liu, Y; Ma, Y; Sun, X; Wang, H | 1 |
2 other study(ies) available for bufogenin and Colorectal Cancer
| Article | Year |
|---|---|
Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation.
Topics: Bufanolides; Carcinogenesis; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Colorectal Neoplasms; Ferroptosis; Humans; Oxidative Stress; Phospholipid Hydroperoxide Glutathione Peroxidase; Reactive Oxygen Species | 2021 |
Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis.
Topics: Animals; Apoptosis; Bufanolides; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Humans; Mice; Necrosis; Neoplasm Metastasis; Receptor-Interacting Protein Serine-Threonine Kinases | 2018 |